T细胞受体
免疫疗法
T细胞
靶向治疗
免疫学
医学
癌症研究
生物
免疫系统
癌症
内科学
作者
Ruihan Xu,Shiyao Du,Junmeng Zhu,Fanyan Meng,Baorui Liu
出处
期刊:Cancer Letters
[Elsevier]
日期:2022-07-31
卷期号:546: 215840-215840
被引量:21
标识
DOI:10.1016/j.canlet.2022.215840
摘要
T cell receptor-engineered T (TCR-T) cells targeting neoantigens present potential immunotherapy for solid tumors. With the continuous optimization of the entire production procedures, the manufacturing process of TCR-T cells is becoming more efficient and productive. However, clinical-scale manufacturing of TCR-T cells still encounters tremendous challenges. Here, we summarize the latest progress of neoantigen-targeted TCR-T cell therapy and focus on the technical difficulties in preparing personalized neoantigen-targeted TCR-T cells and the challenges in clinical applications. Possible approaches for improving TCR-T cell therapy are discussed as well in this review.
科研通智能强力驱动
Strongly Powered by AbleSci AI